Leading industry companies are focused on innovative concepts, combining scientific progress with technical breakthroughs in diagnostics and testing. The introduction of new technological developments and the growth of software for cellular analysis have resulted in increased analytic efficiency and data management. Advanced hematology analyzers can give additional quantitative and qualitative information, such as questionable flags (used to detect errors).
Real-time graphical data enhances efficiency by providing information on aberrant cell populations and illness patterns. For several players, 3D is projected to be an emerging innovation zone. Some hematology analyzers have been developed that use bi-angular laser scatter signals and fluorescence signals to target blood cells and create 3D scattergrams that offer cellular information.
Furthermore, automation has expanded the market for hematology analyzers by allowing for the inclusion of automated ESR (erythrocyte sedimentation rate) systems, integrated slide-makers, hematology stains, HbA1c systems, tube sorters, and digital morphology systems, all of which are linked. All of these reasons point to a significant increase in the market for hematology analyzers over the next 10 years.
Current Technology
A blood sample from the patient must be collected and processed for examination before cells can be counted. To protect the blood from clotting, a phlebotomist collects a blood sample in a test tube coated with an anticoagulant. The blood tube is continually agitated (not shaken) in the laboratory to keep the components from settling during any delays (doing testing on other samples, STAT lab procedures, etc.). Hematology stains are used to stain Red and White Blood cells.
Increasing Awareness Regarding Chronic Diseases to Drive Market Growth
Over the projected period, rising global awareness of chronic illnesses is likely to drive revenue growth in the hematology analyzers market. Chronic illnesses have a high incidence and are the major cause of mortality. The worldwide disease rate is increasing as a result of these illnesses, which is spreading throughout the globe and harming people of all socioeconomic strata. To slow the progression of such diseases, healthcare professionals are concentrating their efforts on early identification and treatment.
Blood analysis has grown in prominence as a means of detecting many chronic illnesses early, which was previously only achievable through tissue biopsy examinations. Advancements in disease-specific blood indicators have aided the growth of the hematology analyzers market.
Regional Outlook of Hematology Analyzers Market
The market for hematology analyzers is obviously dominated by North America, and this trend is projected to continue during the forecast period. However, in the East Asia area, the development of local competitors and the availability of less expensive automated hematological equipment would assist its quick expansion over the projection period. While enhanced technology is driving the growth of the hematology analyzers market in North America, growing illness prevalence and an aging population are driving the market in East Asia.
Regulations playing in the market for Hematology Analyzers
Most hematology analyzers discussed in this article fall within the moderately complicated regulatory category under the Clinical Laboratory Improvement Amendments (CLIA). Users of this type of equipment must have a basic level of scientific and technical knowledge and training in order to execute their responsibilities correctly.
The test procedures are either done automatically (as is the case with most analyzers) or are simply managed, requiring minimum interpretation and technician review. These standards and limits apply to the laboratory’s operation, testing facilities, and test-taking employees. CLIA, CAP, and the US Food and Drug Administration (FDA) make no attempt to regulate or create credentials for those who use these analyzers.
While CAP has maintenance requirements that must be met in order to be certified, neither they nor FDA specifies who is responsible for maintaining laboratory equipment. Maintainer qualifications and credentials are addressed only by the Joint Commission, which is not a regulatory agency.
Risk Management Issues for Hematology Analyzers
Hematology analyzers have no more risk management difficulties than other clinical laboratory equipment. The major dangers include erroneous findings, which might lead to therapy delays or improper treatment. When assessing risk, the equipment manager should always err on the side of caution.
Service Training and Equipment
Despite the fact that lab technicians undergo significant training in operator maintenance, biomes may be called upon to maintain hematology analyzers on occasion. Hard failures, or the irreversible breakdown of a significant section of the instrument, are the most common failures experienced by in-house maintainers. Device-specific training is particularly suggested in these situations.
If this is not possible, knowledge of the test technique and lab equipment expertise, as well as good service literature, are the next best options; technical phone support from the manufacturer can also be beneficial. Good service literature is helpful even with model-specific training. In the absence of both, the in-house Bio-med can diagnose and fix the most common issues, such as unserviceable power supplies, open and shorted power transistors, burned-out motors, and so on.
Conclusion
Hematology analyzers will continue to rule the worldwide market. While point-of-care devices are in high demand, standalone devices will account for a bigger portion of the market. Collaborations with distributors, as well as the launch of new goods with a focus on the creation of innovative gadgets, are important focus areas for top market players that will considerably enhance growth during the projection period.
